SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 60.5% in December

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 1,700 shares, a decline of 60.5% from the November 30th total of 4,300 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is presently 0.1 days.

SAB Biotherapeutics Trading Down 11.1 %

SABSW opened at $0.08 on Friday. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19. The stock has a 50-day moving average of $0.06 and a 200-day moving average of $0.05.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.